Biotechnology - Lemtrada, Neurological

Filter

Current filters:

LemtradaNeurological

Popular Filters

Genzyme gains UK NICE backing for second MS drug Lemtrada

Genzyme gains UK NICE backing for second MS drug Lemtrada

28-05-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

AubagioBiotechnologyGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

Genzyme to resubmit Lemtrada NDA for FDA review

Genzyme to resubmit Lemtrada NDA for FDA review

07-04-2014

Genzyme, the biotech subsidiary of French drug major Sanofi, said this morning that, following “constructive…

BayerBiotechnologyLemtradaNeurologicalNorth AmericaRegulationSanofiUSA

UK’s NICE says “yes” to Genzyme’s MS drug Lemtrada

04-04-2014

In final draft guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE)…

BiotechnologyGenzymeLemtradaNeurologicalNorthern EuropeRegulationSanofiUK

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

05-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

BiotechnologyEuropeGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

Genzyme's MS drug Lemtrada approved in Europe

17-09-2013

French drug major Sanofi (Euronext: SAN) and its USA-based biotech subsidiary Genzyme revealed this morning…

AubagioBiotechnologyEuropeGenzymeLemtradaNeurologicalPharmaceuticalRegulationSanofi

New entrants to multiple sclerosis market will drive 10% pa growth through 2018

26-07-2013

The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio

28-01-2013

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

News briefs from Sanofi, Biogen/SOBI and Novartis

01-11-2012

French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

FDA calls on Genzyme to re-file Lemtrada sBLA

28-08-2012

French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

European neurologists view Rxing of Biogen Idec's BG-12, Sanofi's Aubagio and Sanofi/Bayer's Lemtrada

26-06-2012

More than 85% of surveyed neurologists in the European Union-5 (France, Germany, Italy, Spain and the…

AubagioBayerBG-12Biogen IdecBiotechnologyEuropeLemtradaMarkets & MarketingNeurologicalPharmaceuticalSanofi

Genzyme files multiple sclerosis drug Lemtrada with FDA and EMA

12-06-2012

French drug major Sanofi (Euronext: SAN) subsidiary Genzyme revealed this morning that it has submitted…

BayerBiotechnologyEuropeGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif

24-10-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) saw its shares jump 6% to $107.53 last Friday, after the company…

AlemtuzumabBiogen IdecBiotechnologydaclizumabdimethyl fumarateGenzymeLemtradaNeurologicalPharmaceuticalResearchSanofi

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top